Five Prime

FPRX NASDAQ
5.90
-0.48
-7.52%
盘后: 5.90 0 0.00% 16:23 06/14 EDT
开盘
6.41
昨收
6.38
最高
6.41
最低
5.80
成交量
91.02万
成交均量(3M)
35.12万
52周最高
17.88
52周最低
5.80
换手率
2.52%
市值
2.13亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Five Prime FPRX股票价格,Five Prime股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
展开 >

最近浏览

名称
价格
涨跌幅